TP53 and acute myeloid leukemia: APR-246 showed a potential activity in TP53-mutated MDS/AML in a phase Ib/II study (ORR 73% and CR 50% in TP53-mutated MDS and ORR 64% and CR 36% in TP53-mutated AML) [77] and another phase II study (ORR 62% and CR 47% in TP53-mutated MDS and ORR 33% and CR 17% in TP53-mutated AML) [78].